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Dengue virus (DENV) is a rapidly spreading pathogen with unusual
pathogenesis, and correlates of protection from severe dengue
disease and vaccine efficacy have not yet been established.
Although DENV-specific CD8+ T-cell responses have been exten-
sively studied, the breadth and specificity of CD4+ T-cell responses
remains to be defined. Here we define HLA-restricted CD4+ T-cell
epitopes resulting from natural infection with dengue virus in a
hyperepidemic setting. Ex vivo flow-cytometric analysis of DENV-
specific CD4+ T cells revealed that the virus-specific cells were highly
polarized, with a strong bias toward a CX3CR1+ Eomesodermin+
perforin+ granzyme B+ CD45RA+ CD4 CTL phenotype. Importantly,
these cells correlated with a protective HLA DR allele, and we dem-
onstrate that these cells have direct ex vivo DENV-specific cytolytic
activity. We speculate that cytotoxic dengue-specific CD4+ T cells
may play a role in the control of dengue infection in vivo, and this
immune correlate may be a key target for dengue virus vaccine
development.
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All four of the dengue virus serotypes (DENV 1–4) have spreadrapidly within countries and across regions in the past few
decades, resulting in an increased frequency of epidemics and se-
vere dengue disease. Multiple serotypes circulate simultaneously in
many tropical countries, and recent outbreaks have been reported
in Europe and the continental United States (1, 2). These circum-
stances make dengue the most prevalent and rapidly spreading
mosquito-borne viral disease in humans (3). Recent reports es-
timate that 390 million infections occur each year, with ∼25% of
cases resulting in symptomatic disease (2).
All four dengue serotypes can cause a spectrum of disease,
ranging from self-limiting dengue fever to potentially lethal severe
dengue disease, such as states of dengue hemorrhagic fever and
Dengue shock syndrome, which are associated with the plasma
leakage syndromes leading to visceral organ injury (4). It is not yet
fully understood why only a subset of people infected with DENV
progresses to severe disease. One risk factor for severe disease is the
acquisition of DENV-reactive Abs before secondary infection with
a different serotype (heterologous infection). These Abs can either
be acquired from a previous infection with a different serotype or,
in the case of infants, acquired from an immune mother (5, 6). It
has been shown that subneutralizing levels of DENV-specific Abs
exacerbate disease in a phenomenon termed Ab-dependent en-
hancement of infection (7, 8). In brief, dengue-specific cross-
reactive Abs produced after an initial DENV infection combine
with those produced after a second viral infection to form immune
complexes that perpetuate infection by increasing the number of
infected cells and, therefore, viral output per cell (6).
The observation that only a minority of patients develops severe
disease suggests that host genetic factors may play an important role
in disease severity. Relatedly, a role for T cells in control of disease
has been suggested by several studies that correlate the expression
of certain HLA molecules with susceptibility to or protection from
DENV disease (9–15). HLA molecules are one of the most poly-
morphic host factors in humans, with several thousand variants thus
far known (16, 17). Each HLA variant is present with variable
frequency, depending on ethnic lineage and geographic locality. For
HLA class I MHC restricted responses, it has been recently shown
that different allelic variants are associated with differential mag-
nitude of anti-DENV responses and that HLA alleles known to be
associated with increased risk of severe DENV disease are associ-
ated with weaker CD8+ T-cell responses (18). Similarly, certain
MHC class II alleles have been described as associated with
increased protection from severe disease (9, 15, 19–21). Thus,
T-cell responses are likely to contribute to protection from dengue
disease.
In this study, we defined HLA-restricted CD4+ T-cell re-
sponses resulting from natural infection with DENV. We iden-
tified cytotoxic subsets of DENV-specific effector memory CD4+
T cells that are specifically expanded as a function of history of
DENV infection and in donors carrying an HLA allele associ-
ated with protection from severe DENV disease.
Results
Definition of a Screening Strategy for HLA Class II DENV-Specific CD4+
T-Cell Responses. DENV is hyperendemic in Sri Lanka, with
∼80% of the general population seropositive by the age of 18,
with the majority of people showing neutralizing Ab patterns
characteristic of multiple infections (18). To analyze DENV-
specific CD4 responses, we selected a set of DENV peptides
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predicted to bind the DRB1*0701 allele, which is highly preva-
lent in Sri Lanka (33% phenotypic frequency). These peptides
were tested by using HLA-matched peripheral blood mono-
nuclear cell (PBMC) donations from blood donors from the
Colombo blood bank.
In contrast to the case of previously described CD8+ T-cell
responses (18), we did not readily detect CD4+ responses directly
ex vivo using a standard IFN-γ enzyme-linked immunospot
(ELISPOT) assay. This result was expected, because it has been
shown for several human viral infections that the frequency of
CD4+ T cells is generally lower than CD8+ T cells, and therefore
in vitro expansion is often required. Accordingly, PBMCs from
HLA DRB1*0701 individuals—either seronegative or associated
with primary or secondary infections—were stimulated in vitro
with DRB1*0701-restricted peptide pools. To minimize the po-
tential for detecting responses arising from primary in vitro
stimulation, naïve CD4+ T cells were removed before stimulation
based on expression of CD45RA.
Using reactivity of seronegative individuals, we established a
threshold for positivity of 320 spot-forming cells (SFCs). This
threshold was >99% of individual responses; thus, responses
above this threshold are expected to occur with a false positive
rate of 0.01 (Fig. 1A). As expected, we could detect multiple
positive memory responses in the CD45RA− subset in donors
associated with primary DENV infection (Fig. 1B). However, to
our surprise, the majority of CD4+ T-cell responses after sec-
ondary infection were detected in the CD45RA+ CD4+ T-cell
subset (Fig. 1C).
In the same series of experiments, we also tested peptides
predicted to bind DRB1*0401 and *0802 alleles. These two al-
leles were selected because they are associated with increased
resistance (DRB1*0401) or susceptibility (DRB1*0802) to se-
vere DENV clinical outcomes (9, 15, 22) In the case of the
DRB1*04-protective allele and secondary infections, responses
were most vigorous and associated with the CD45RA+ subset,
thus resembling the pattern observed in the DRB1*07 responses
(Fig. 1 D and E). By contrast, DRB1*08 restricted responses
were weak in the primary infection and mostly associated with
the CD45RA− subset in the case of secondary infections (Fig. 1 F
and G). Statistical analyses are shown in Fig. 1H.
To exclude that differences in MHC binding account for the
allele-specific differences, we measured the binding affinity of all
predicted peptides to the respective HLA allele. For all HLA
alleles, >89% of the predicted peptides bound with 1,000 nM or
less, which corresponds to the biological threshold for efficient
binding to a MHC class II molecules (23) (Fig. S1). No major
differences in binding affinity between HLA alleles were ob-
served, with the average IC50 being 28 for DRB1*0701, 34 for
DRB1*0401, and 47 for DRB1*0802.
Because secondary infection is associated with more consistent
immunity from both homologous and heterologous infection, the
response magnitude and the CD45RA+ phenotype seemed to
correlate with protection from severe DENV disease.
Expansion of Memory T-Cell Subsets in DENV Secondary Infection.
The design of HLA-specific epitope pools to enhance the fre-
quency of responding T cells (as opposed to generic peptide
pools) allowed us to readily and consistently detect ex vivo re-
activity using intracellular cytokine staining (ICS). First, we ex-
amined the magnitude of response as a function of the donor
infection history in a total of 37 different donors (Fig. 2A). No
responses (<0.02%) were observed in DENV-seronegative do-
nors, whereas on average 0.07% of total CD4+ T cells from
primary infection cases produced IFN-γ upon epitope stimula-
tion. As expected, the most vigorous responses were observed in
the donors associated with secondary infections (0.13% on av-
erage). We then used the surface markers CCR7 and CD45RA
to establish to which memory subset the responding T cells
Fig. 1. Subset-specific CD4 T-cell responses after in vitro restimulation
were determined by HLA restriction and DENV infection history. PBMC
were thawed, and CD4+ T cells were isolated by magnetic bead negative
selection. CD45RA+ and CD45RA− cells were subsequently isolated by
magnetic bead selection and cocultured with autologous APCs and with
DENV-specific pools (averaging 20 peptides per pool). On day 14, cells were
harvested and screened for reactivity against individual DENV-specific
peptides in an IFN-γ ELISPOT. (A) Eight DENV-negative donors were stim-
ulated with HLA-matched peptide pools and tested for reactivity against
individual peptides. The reactivity of seronegative individuals that was
>99% of all individual responses (SFC = 320; dashed line) was used to
define a threshold value for positivity corresponding to a P value of 0.01
for false positives. (B–G) CD45RA+ (red bars) and CD45RA− (black bars)
CD4+ T cells from donors expressing the DRB1*0701 (B, n = 4; and C, n = 7),
DRB1*0401 (D, n = 5; and E, n = 6), or DRB1*0801 (F, n = 2; and G, n = 6)
allele and have experienced either primary (1°) or secondary (2°) infection
with DENV were stimulated with HLA-matched peptide pools and tested
for reactivity against individual peptides. Error bars represent mean ±
SEM. (H) The sum of responses adjusted by the number of donors tested
for each HLA is shown as a function of infection history. Significance of
CD45RA+ (red bars) and CD45RA− (black bars) responses was compared in a
two-tailed Mann–Whitney test.



























belonged (24). Fig. 2B shows representative data for one donor,
showing the expression patters of CCR7 and CD45RA in total
CD4+ T cells (black dots) and antigen-specific cells after stim-
ulation with a pool of DR-restricted epitopes (IFN-γ; red
dots). Effector memory T-cell subsets, defined by the loss of
CCR7, were associated with 57% (CCR7− CD45RA−) and 27%
(CCR7−CD45RA+) of the response, respectively, whereas neg-
ligible amounts of the DENV-specific responses were attributed
to naïve (CCR7+ CD45RA+) and central memory (CCR7+
CD45RA−) T-cell subsets. Interestingly, in this donor 10% of the
total CD4+ T cells were associated with the CCR7−CD45RA+
effector memory subset. Previous studies reported this subset to be
present at 2.3 ± 1.1% (CD4+CD45RA+CCR7–) in a group of
randomly selected healthy donors, such that the expansion of this
subset in DENV-infected donors was somewhat unexpected
(25). When gated on the individual memory subset, the CCR7−
CD45RA+ subset produced significantly more IFN-γ compared
with the other two memory populations. (Fig. 2C; P < 0.001 in a
Mann–Whitney test).
We extended these observations by measuring the percentage
of total CD4+ T cells associated with each memory subset in
seronegative individuals or in persons determined to have pre-
vious primary or secondary DENV infections. Multiple DENV
infections (2° DENV) were marked by a significant and pro-
gressive increase of the CCR7−CD45RA+ subset (Fig. 2D). The
fraction of CD4+ T cells associated with this phenotype was
negligible in DENV-seronegative individuals, increased in in-
dividuals associated with primary infection, and reached an av-
erage of 6.5% (0.6–21.3% range) in donors associated with
secondary infection (Fig. 2E). A similar trend was also noted in
the case of the other effector memory subset (CCR7−CD45RA−;
Fig. 2F). By contrast, the fraction of CD4+ T cells associated with
a central memory phenotype (CCR7+CD45RA−) did not vary
appreciably as a function of DENV infection history (Fig. 2G).
Fig. 2. DENV-specific responses and memory T-cell subsets change as a function of infection history and restricting HLA alleles. (A) PBMCs from the Sri Lanka
cohort (n = 37) were stimulated with HLA-matched peptides for 6 h, and the IFN-γ responses were measured by ICS. Responses are shown as a function of the
donors’ exposure to the dengue virus [DENV-negative (n = 4) and primary (1°; n = 11) and secondary (2°, n = 22) DENV infection]. (B) Representative staining
of the memory CD4+ T cells subsets and IFN-γ–producing cells of a secondary donor is shown. Memory subsets were defined as naïve T cells (CCR7+CD45RA+),
central memory T cells (CCR7+CD45RA+), and the two effector memory subsets (CCR7−CD45RA− and CCR7−CD45RA+), according to their expression of these
markers. (C) The IFN-γ response of each memory T-cell subset was measured by ICS after stimulation with HLA-matched peptides (n = 23). (D) Representative
FACS plots of CD4+ T-cell subsets in donors with a DENV-negative, (1°) primary or (2°) secondary DENV infection history are shown. (E–G) Distribution of CD4+
memory T-cell subsets in negative, primary, and secondary donors are shown (E, CCR7−CD45RA+; F, CCR7−CD45RA−; G, CCR7+CD45RA+, n = 28). (H) Percentage
of total CD4+ T cells that produce IFN-γ upon stimulation with HLA-matched peptides in donors carrying the DRB1*0802, DRB1*0701, or DRB1*0401 allele.
(I and J) The ability of CCR7−CD45RA+ (I) and CCR7−CD45RA− (J) subsets to produce IFN-γ upon peptide stimulation was measured for donors expressing
DRB1*0802, DRB1*0701, and DRB1*0401 alleles (n = 24). (K and L) The size of the total CD4+ CCR7−CD45RA+ (K) and CCR7−CD45RA− (L) subsets were also
measured for each allele. Error bars represent mean ± SEM. Statistical significance was determined by using the two-tailed Mann–Whitney test.
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We then compared the percentage of total CD4+ T cells that
produce IFN-γ upon stimulation with HLA matched DENV
peptides in donors carrying either the DRB1*0802, DRB1*0701,
or DRB1*0401 allele. No significant difference between the
HLA alleles could be observed (Fig. 2H). However, when we
compared the magnitude of IFN-γ DENV-specific responses for
memory subsets for each HLA DR allelic variant, we found that
in the case of the DRB1*04-protective allele, CCR7−CD45RA+
effector memory cells were expanded compared with the DRB1*08-
susceptible allele (P = 0.02; Fig. 2I), whereas no HLA-specific
differences have been detected in IFN-γ+CCR7−CD45RA−
memory cells (Fig. 2J). This trend was specifically associated with
DENV-specific IFN-γ+ cells, because no significant association
between protective and susceptible alleles was noted in the case
of total CCR7−CD45RA+ and CCR7−CD45RA− subsets (Fig. 2
K and L). In conclusion, an expansion of the CCR7−CD45RA+
effector memory subsets is associated with measured IFN-γ
responses as a function of DENV infection history and associ-
ated with expression of protective HLA alleles.
Expanded CD4 T-Cell Populations in DENV-Exposed Individuals Are
Associated with a Cytotoxic Phenotype. Given the marked increase
in CCR7−CD45RA+ CD4 T-cell frequencies in dengue 2° subjects,
and particularly the association of DENV-specific IFN-γ+CCR7−
CD45RA+ CD4 T cells with protective alleles, we sought to further
characterize the biology and function of these cells. The function of
effector and memory T cells is dependent on the capacity to migrate
to sites of antigen encounter. Chemokine receptors have been
particularly useful for dissecting T-cell subsets with distinct migra-
tory capacity and effector function (26). Accordingly, in the next
series of experiments, we characterized DENV-specific T cells for
the expression of chemokine receptors that are commonly used to
define functional subsets of T helper (Th) cells, defined as CXCR3+
CCR6− (Th1), CCR4+CCR6− (Th2), CXCR3+CCR6+ (Th1/17),
CCR4+CCR6+ (Th17), and CXCR5+ (Tfh) cells, respectively
Fig. 3. Expanded CD4 T-cell populations in DENV-exposed individuals are associated with a cytotoxic phenotype. (A–D) PBMC were stimulated with HLA-
matched peptides for 6 h, and the IFN-γ responses were measured by ICS. CD4 effector memory cells (CCR7−CD45RA+ and CCR7−CD45RA−) were defined as
Th1 (CXCR3+CCR4−CCR6−), Th2 (CXCR3−CCR4+CCR6−), Th17 (CXCR3−CCR4+CCR6+), Th1/17 (CXCR3+CCR4−CCR6+), and Tfh (CXCR5+) subsets, according to the
expression of these surface markers. The chemokine receptor expression for IFN-γ–producing CCR7−CD45RA+ (A) and CCR7−CD45RA− (C) effector memory
cells is shown (n = 5). The distribution of CD4+ Th subsets in DENV-negative (filled circles; n = 9) and donors experiencing secondary infection with DENV (2°;
open triangles; n = 10) for the effector memory subsets CCR7−CD45RA+ (B) and CCR7−CD45RA− (D) is shown (n = 10). (E–J) PBMCs from donors who were
found to be dengue-negative (neg.; filled circles) or having experienced a secondary infection (2°; DENV infection; triangles) were stained for memory
markers, IFN-γ production, and markers for effector function. Shown are expression of the specific marker in CD4 T-cell subsets (Left), representative FACS
plots (Center), and the expression in DENV-specific IFN-γ–producing CD4 T cells (Right). (E) CD226 expression was measured and compared among DRB1*04:01
secondary donors (n = 5), DRB1*08:02 secondary donors (n = 3), and DENV-negative donors (n = 5). Expression was compared between naïve cells and
memory subsets, as well as between bulk CD4+ and IFN-γ–producing CD4+ T cells. Similar analysis was carried out for TIGIT (F), CD107a (G), perforin (H),
granzyme B (I), and CD8α (J). (K) Transcription factors Tbet and Eomes were stained, and their joint expression was compared among CD4+ subsets, with
representative plots shown. Error bars represent mean ± SEM. Statistical significance was determined by using the two-tailed Mann–Whitney test.



























(26, 27). Surprisingly, the majority of IFN-γ–producing cell
were not found in any of the conventional Th subsets. In the
case of CCR7−CD45RA+cells, >50% of the DENV-specific
IFN-γ T cells were negative for CCR6, CCR4, and CXCR3
(Fig. 3A). When we examined the expression of CCR6, CCR4,
and CXCR3 of total CD4+ T cells from DENV-seronegative
and in samples from individuals with secondary DENV
infection, a highly significant expansion of CCR6−, CCR4−, and
CXCR3− cells was detected (P = 0.0009; Fig. 3B). These results
were essentially mirrored in the case of CCR7−CD45RA− cells
(Fig. 3 C and D).
Because we could not associate the majority of DENV-specific
CD4+ T cells with common Th subsets, we hypothesized that they
might be associated with cytotoxic function, as has been described in
a murine system (28, 29). Accordingly, we further characterized the
expression of various phenotypic markers associated with cytotoxic
T-cell function. Each marker was evaluated by flow cytometry,
comparing donors with secondary DENV infection expressing
either DRB1*0401 or DRB1*0801 alleles. DENV-negative donors
were used as a control (Fig. 3 E–K). Each panel shows expression of
the specific marker in CD4 T-cell subsets as well as in DENV-
specific IFN-γ–producing CD4 T cells.
T cells with cytotoxic function have been previously charac-
terized to express a number of cell-surface and intracellular
markers including high CD107, CD226, Perforin, and low TIGIT.
As shown in Fig. 3E, CD226 was highly expressed in the CCR7−
effector memory subsets. Conversely, TIGIT expression was
correspondingly low, being most pronounced in the case of sec-
ondary infection and the protective DRB1*0401 allele (Fig. 3F;
P = 0.03). The degranulation marker CD107 was also significantly
Fig. 4. DENV-specific CD4+ T cells express CX3CR1 and mediate direct cytotoxic activity. (A) The relative expression of CX3CR1 was measured in the four T cells
subsets in DRB1*0401 donors with a history of secondary DENV infection donors (n = 8). (B) A representative dot plot of total CD4+ (black dots) is overlaid with
CX3CR1 expression (red dots). (C) CX3CR1 expression in total CD4+ T cells and DENV-specific IFN-γ–producing cells is shown (n = 5). (D) CX3CR1+ and naïve
CD4+ T cells were sorted and cultured with peptide pulsed APCs overnight at 37 °C. Cells were then harvested, stained for HLA-DR, and analyzed by flow
cytometry. The difference in absolute numbers of HLA-DR expressing APCs cocultured with either naïve CD4+ T cells or CXCR3+ cells was then expressed as
percentage of killing (n = 3). Error bars represent mean ± SEM. Statistical significance was measured by using a two-tailed Mann–Whitney test. (E) Proposed
model of cytotoxic CX3CR1+ T-cell differentiation. Naïve CD4+ T cells (CD45RA+CCR7+) get activated during primary infection with DENV (red hexagons) and
differentiated into effector T cells (CD45RA−CCR7−). Upon continuous reexposure to heterologous DENV infections (yellow hexagons), effector memory T cells
down-regulate CD28, CD45RO, CD127, and TIGIT. CD8α, CD57, CD107, and CD226, as well as perforin, granzyme B and the transcription factors T-bet and
Eomes are up-regulated in highly differentiated effector memory T cells (CD45RA+CCR7−).
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up-regulated in donors that had experienced secondary infection
with DENV (P = 0.002 for *0401 and P = 0.04 for *0802,
respectively; Fig. 4G) and specifically up-regulated in DENV-
specific IFN-γ–producing cells compared with total CD4+ T
cells (P = 0.04).
Perforin and granzyme B expression was also selectively enriched
in CCR7−CD45RA+ CD4+ T cells in donors expressing the pro-
tective DRB1*0401 allele, compared with those expressing the sus-
ceptible DRB1*0801 allele (P = 0.02 and 0.007 for perforin and
granzyme B, respectively; Fig. 3 H and I). Furthermore, granzyme B
was also selectively up-regulated in the DENV-specific T cells, as
identified by DENV-specific IFN-γ secretion (P = 0.02). Finally, it
has been shown that highly differentiated CD4 cytotoxic T cells often
coexpress CD8α (28). Accordingly, we tested for expression
of this marker. As shown in Fig. 3J, up to 40% of the cells of
CCR7−CD45RA+ express CD8α in donors that express DRB1*0401.
Furthermore, CD8α was also up-regulated in DENV-specific cells
compared with total CD4+ T cells (P = 0.001). Further character-
ization of these subsets in DENV-negative and -positive donors
revealed a highly differentiated phenotype evidenced by down-
regulation of CD28, CD45RO, and CD127, whereas CD57
expression was high (Fig. S2).
Because the T-box transcription factors T-bet and Eomeso-
dermin (Eomes) are known to induce multiple cytolytic functions in
CD4+ T cells, we next examined coexpression of these factors
within CD4+ T-cell subsets (30, 31). Both transcription factors were
coexpressed significantly higher in CCR7−CD45RA+ cells (P =
0.003; Fig. 3K) further suggesting the cytotoxic phenotype CD4
T-cell differentiation programming indicated by the other markers.
These phenotypic traits of the DENV-specific CD4 T cells are
largely in accordance with those of cytolytic CD4+ T cells found in
latent infection with human cytomegalovirus (CMV). To compare
the cytotoxic profiles we have tested multiple DRB1*0401 donors
with a peptide pool containing CMV-specific peptides. CMV-spe-
cific IFN-γ+ responses have been detected in four of seven donors
tested. The phenotype and cytotoxic profiles in these four donors
have subsequently been analyzed (Fig. S3A). As expected, we saw
the majority of CMV-specific responses originate from the effector
memory subsets (Fig. S3 B and C). As seen with dengue specific
cells also the majority of CMV-specific cells did not express the
chemokine markers CXCR3, CCR4, or CCR6 (Fig. S3D). CMV-
specific cells further expressed significantly more CD107, perforin,
and granzyme compared with the total CD4 T cells. No difference
has been observed in the expression of CD226 and TIGIT. In
contrast to DENV-specific cells, CMV-specific cells did not signif-
icantly up-regulate CX3CR1, and IFN-γ+ CD4 cells coexpressed
significantly less CD8α (Fig. S3 E–K).
DENV-Specific CD4+ T Cells Express CX3CR1 and Mediate Direct
Cytotoxic Activity. Given that the DENV-specific CD4 T cells
did not express any of the CD4 T-cell chemokine markers from
our conventional panel, we considered whether other receptors
might be expressed. The CX3CR1 chemokine receptor has been
implicated in the trafficking and adhesion of lymphocytes and
lymphocyte survival and maintenance in inflamed tissues (32).
We measured the expression of this chemokine receptor in
secondary DENV infection samples. The fraction of CX3CR1+
effector memory cells was highest in CCR7−CD45RA+ cells
(Fig. 4A). Similarly, whereas only ∼10% of total CD4+ T cells
expressed CX3CR1, almost 50% of the DENV-specific IFN-
γ–producing cells were positive for the expression of this che-
mokine receptor (P = 0.008; Fig. 4C).
We next set out to demonstrate that the DENV-specific HLA
class II restricted CD4+ T cells are not only expressing a pattern
of markers associated with cytotoxicity, but that they can indeed
mediate cell–cell killing. Carboxyfluorescein diacetate succini-
midyl ester (CFSE)-labeled target cells were pulsed with the pool
of DENV epitopes, and the number of DRhi target cells recovered
after overnight incubation with effector cells was measured. As
shown in Fig. 4D, significant killing was observed when sorted
CX3CR1+ T cells from DENVDRB1*0401 donors were used, with
12% (range 9–18%) killing observed at a 5:1 effector:target ratio.
Data from DRB1*0802 individuals, showing a lower activity with
these cells, further helps support the potential implication of a
cytolytic mechanism (Fig. 4D). In summary, we demonstrate that
dengue virus infection elicits highly polarized CX3CR1+ cytotoxic
CD4+ T cells that displays an Eomes+ Tbet+ perforin+ granzyme
B+ CD45RA+ CD4 CTL phenotype (Fig. 4E).
Discussion
These studies describe a human CD4+ T-cell subset than can di-
rectly function as effector cells by executing cytotoxicity in a pep-
tide-specific and MHC class II-restricted manner. This subset is
specifically expanded in donors with a history of DENV infection
and, in particular, in those donors carrying an HLA allele associated
with protection from severe DENV disease. Subpopulations of
cytotoxic CD4+ T cells (CD4–CTL) associated with executing
cytotoxic effector functions have been described, especially under
conditions of chronic viral infections and antitumor reactivity (33–
36). The functional and phenotypic traits of the DENV-specific
CD4 T cells are largely in accordance with those of cytolytic CD4+
T cells found in latent infection with human CMV (HCMV) and
HIV (37, 38). The fact that the phenotype of ex vivo cytotoxic
CD4+ activity after exposure with an acute virus is similar to CD4
T cells in chronic infection points to general validity of this con-
cept. In fact, T cells with granzyme B- and perforin-containing
granules can be found at low frequencies in the circulation of most
healthy individuals (37). This unexpected plasticity of CD4+ T
cells results in the postthymic termination of the Th lineage fate
and the functional differentiation of distinct MHC class II-re-
stricted CD4+ CTL. The development of highly differentiated
cytotoxic CD4 T cells appears to require multiple encounters with
cognate antigen. Infection with one DENV serotype affords life-
long immunity against reinfection with the same serotype. How-
ever, the existence of four different serotypes allows for multiple
encounters with conserved antigens between the serotypes.
Accordingly, we demonstrate that we see a more distinct expan-
sion of this cytotoxic CD4–CTL subset in donors experiencing
multiple infections with different serotypes. This finding is further
supported by the notion that in vitro stimulation of T-cell clones
specific for DENV can result in the generation of cytotoxic CD4
T-cell clones (39–42).
Multiple organ system, such as the liver, and endothelial cell
(EC) linings of blood vessels have been suggested to play an im-
portant role in the pathogenesis of DENV (43). The ligand for
CX3CR1, CX3CL1/fractalkine, is a chemokine synthesized in ECs
as a membrane protein. Membrane-bound fractalkine works as an
adhesion molecule for these leukocytes, and the secreted form as a
chemotactic factor (44). CX3CR1 expression allows migration from
the bloodstream to peripheral tissue (32). This finding could po-
tentially provide a mechanism for how DENV-specific CD4+ T cells
are able to enter and remain in inflamed and infected tissue
throughout the body to exert their prolonged effector functions.
MHC class II molecules are found on antigen-presenting cells
(APCs) such as dendritic cells, phagocytes, ECs, and B cells.
Antigens presented by MHC class II molecules are typically derived
from extracellular proteins. However, it has been shown that
autophagy promotes MHC class II presentation of peptides from
intracellular source proteins (45). Interestingly, one of the mecha-
nisms dengue virus uses to hijack host cell machinery to facilitate
viral replication is by inducing autophagy, which is necessary for
virus maturation and production of infectious virions (46, 47). A
recent study has further provided evidence of a definitive link be-
tween Ab-enhanced DENV infection and autophagosome forma-
tion (48). Cytotoxic CD4+ T cells may contribute to protection by
eliminating these DENV-infected, MHC II-expressing cells.



























In summary, we present the characterization of defined HLA-
restricted CD4+ T-cell responses resulting from natural infection
with DENV in individuals from Sri Lanka where DENV is hyper-
epidemic. This subset is particularly expanded in donors carrying an
allele associated with protection from severe DENV disease. We
are aware that the evidence that these cells are protective is indirect
because it is based on the association with a protective allele.
Knowledge of the HLA alleles associated with increased suscepti-
bility to severe disease has the potential to serve as a prognostic
tool, allowing identification of individuals at increased risk for
severe disease. A detailed characterization of the DENV-specific
T-cell response will further contribute to the evaluation of vaccine
candidates and may contribute to the definition of correlates of
protection from severe disease.
Materials and Methods
Ethics Statement. Blood sampleswere obtained fromhealthy adult blood donors
from the National Blood Center, Ministry of Health, Colombo, Sri Lanka, in an
anonymous fashion. Samples obtained were discarded buffy coats from routine
blood donations at the National Blood Center and thus exempt from human
subject review. The institutional review boards of both La Jolla Institute for Al-
lergy and Immunology (LIAI) and the Medical Faculty, University of Colombo
[serving as the NIH-approved Institutional Review Board (IRB) for Genetech]
approved all protocols described in this study.
Human Blood Samples. The 250 peripheral blood samples were obtained from
healthy adult blood donors from the National Blood Center. Donors were of
both sexes and between 18 and 60 y of age. Blood processing and HLA typing
of both study populations were performed as described (18). PBMCs of do-
nors were picked according their expression of one of the HLA alleles
studied. The institutional review boards of both LIAI and the Medical Fac-
ulty, University of Colombo (serving as NIH-approved IRB for Genetech)
approved all protocols described in this study.
Serology. DENV seropositivity was determined by dengue IgG ELISA as described
(49). Flow cytometry-based neutralization assays were performed for further
characterization of seropositve donors, as described (50). Neutralization assays
determined that the majority of donors have experienced infection with more
than one serotype, further referred to as secondary infections. Donors that
showed neutralization titers to only one of the serotypes were considered
primary infections.
MHC Class II Binding Predictions and Peptide Selection. To analyze DENV-spe-
cific HLA-restricted CD4 responses, we selected a set of DENV peptides predicted
to bind HLA DRB1*0701, chosen because of its high prevalence in Sri Lanka (33%
phenotypic frequency). Two additional alleles were selected because they are
respectively associated with increased resistance (DRB1*0401) or susceptibility
(DRB1*0802) to severe DENV clinical outcomes (9). The 15-mer peptides from all
serotypes were predicted for their binding affinity to the selected MHC class II
molecules. Epitope predictions for class II were performed for DENV1, 2, 3, and 4
for all isolates in the database by using the consensus prediction methods
publicly available through the Immune Epitope Database and Analysis Resource
(IEDB; www.iedb.org) (51, 52). For each allele, any peptide predicted to bind
with high affinity (2% consensus threshold) and that was present in 30% or
more of the isolates was synthesized. This approach resulted in the synthesis of
148 DRB1*0701, 132 DRB1*0401, and 142 DRB1*0802 peptides (Mimotopes). For
screening studies, the class II peptides were combined into pools of ∼20 indi-
vidual peptides, according to their predicted HLA restriction, resulting in seven
pools per HLA allele. CMV-specific MHC class II peptides were selected through
the IEDB.
MHC Purification and Binding Assays. Purification of HLA class II MHC mole-
cules by affinity chromatography and the performance of assays based on the
inhibition of binding of a high-affinity radiolabeled peptide to quantitatively
measure peptide binding were performed essentially as detailed elsewhere
(53). Briefly, EBV-transformed homozygous cell lines were used as sources of
MHC molecules. A high-affinity radiolabeled peptide (0.1–1 nM) was coin-
cubated at room temperature or 37 °C with purified MHC in the presence of
a mixture of protease inhibitors. After a 2-d incubation, MHC bound ra-
dioactivity was determined by capturing MHC/peptide complexes on Ab-
coated Lumitrac 600 plates (Greiner Bio-one) and measuring bound cpm
using the TopCount (Packard Instrument Co.) microscintillation counter. The
concentration of peptide yielding 50% inhibition of the binding of the ra-
diolabeled peptide was calculated (IC50). As a positive control, the unlabeled
version of the radiolabeled probe was also tested in each experiment.
In Vitro Expansion of DENV-Specific T Cells. PBMCs were thawed, and CD4+ T
cells were isolated by magnetic bead negative selection. CD45RA+ and
CD45RA− cells were subsequently isolated by magnetic bead selection and
cultured separately in RPMI 1640 (Omega Scientific) supplemented with 5%
(vol/vol) human serum (Cellgro) at a density of 2 × 106 cells per mL in 24-well
plates (BD Biosciences). Cells were cocultured with autologous APCs at a
density of 1× 106 cells per mL and stimulated with DENV-specific pools (av-
eraging 20 peptides per pool). Cells were kept at 37 °C in 5% CO2, and
additional IL-2 (10U/mL; eBioscience) was added 4, 7, and 11 d after initial
antigenic stimulation. On day 14, cells were harvested and screened for re-
activity against individual DENV-specific peptides.
IFN-γ ELISPOT Assay. After 14 d of in vitro expansion, 5 × 104 PBMCs were
incubated in triplicate with 0.1 mL of complete RPMI 1640 in the presence of
HLA-matched peptide pools and individual peptides (2 μg/mL). After a 20-h
incubation at 37 °C, the cells were incubated with biotinylated IFN-γ mAb
(mAb 7-B6-1 Mabtech) for 2 h and developed as described (18).
Flow Cytometry.Detailed information of all mAbs used in this study is listed in
Table S1. For ICS, PBMCs were cultured in the presence of HLA-matched
peptide pools (10 μg/mL) and GolgiPlug containing brefeldin A (BD Bio-
sciences) for 6 h and subsequently permeabilized, stained, and analyzed as
described (18). Staining for intracellular nuclear proteins was performed by
using the Foxp3/Transcription Factor Staining Buffer Set according to the
manufacturer’s instructions (eBioscience).
In Vitro Cytotoxicity Assay. For the cytotoxicity assay, cells were surface-
stained and sorted with the FACSAria III (BD Biosciences). Effector memory
CD4 T cells (CD3+, CD4+, CCR7−, and CX3CR1+) and naïve CD4 T cells (CD3+,
CD4+, CCR7+, and CD45RA+) were sorted as the effector cells and APCs
(CD3-) sorted as targets. APCs were then stained with CFSE (Life Technolo-
gies) at a concentration of 5 μM for 20 min at room temperature and pulsed
with peptide (10 μg/mL) for 60 min at 37 °C. The APCs and effectors were
cocultured overnight at 37 °C. Cells were then harvested, stained for HLA-
DR, and analyzed by flow cytometry.
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